Editorial
Carbon Monoxide or Nitric Oxide: Which Came First?
Abstract
Pulmonary hypertension has a poor prognosis with mortality, ranging as high as 50%. Echocardiograms, measures of pulmonary artery pressures, and ventilation-perfusion scans (V/Q scan) offer the most definitive diagnosis and assessment of disease progression and treatment progress. This pathology is characterized by dyspnea and tachypnea, as well as symptoms of congestive heart failure such as edema, hepatomegaly, and jugular vein distention.1 Pulmonary hypertension can lead to acute respiratory distress syndrome (ARDS). This is characterized by dyspnea and hypoxemia caused by intrapulmonary shunting and V/Q mismatch. Inhaled nitric oxide (INO) is used to reduce pulmonary vascular resistance and the resulting hypoxemia.2This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.